

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



CNX-774

Item No. 21475

CAS Registry No.: 1202759-32-7

Formal Name: 4-[4-[[5-fluoro-4-[[3-[(1-oxo-2-propen-

1-yl)amino|phenyl|amino|-2-pyrimidinyl|

amino]phenoxy]-N-methyl-2-

pyridinecarboxamide

MF: $C_{26}H_{22}FN_7O_3$

499.5 FW: **Purity:** UV/Vis.:

 λ_{max} : 272 nm A crystalline solid Supplied as:

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CNX-774 is supplied as a crystalline solid. A stock solution may be made by dissolving the CNX-774 in the solvent of choice. CNX-774 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CNX-774 in these solvents is approximately 25 and 30 mg/ml, respectively.

CNX-774 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CNX-774 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CNX-774 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CNX-774 is a potent, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), an important kinase in the B cell antigen receptor pathway, with IC_{50} values of <1 nM in biochemical assays and 1-10 nM in cellular assays. It inhibits proliferation in HMC-1.1 and HMC-1.2 cells (IC₅₀ = 2.82 and 0.38 μ M) but has no effect on cell cycle progression.2

References

- 1. Akinleye, A., Chen, Y., Mukhi, N., et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 6(59) (2013).
- 2. Smiljkovic, D., Blatt, K., Stefanzl, G., et al. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. Allergy 1-11 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 05/08/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM